IP Library Granted Patent US 11,339,111
Granted Patent B2
US 11,339,111 · App. 16/767,735 · Granted May 24, 2022

Polyketide compound and derivatives thereof for use in the prevention and treatment of a neurological disorder

Inventors: Denis Marcel Barron (Lutry, CH); Olivier Ciclet (Veyrier, CH); Alexandre Grand-Guillaume-Perrenoud (Preverenges, CH); Martine Naranjo Pinta (Morges, CH); Yann Ratinaud (Morges, CH); Jonathan Thevenet (Publier, FR); Andreas Wiederkehr (Blonay, CH)
Assignee: Societe des Produits Nestle S.A.
C07C59/92C07D313/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,339,111
App. No.
16/767,735
Granted
May 24, 2022
Kind
B2
Abstract

The present invention relates to a compound, in particular a polyketide compound and derivatives thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition are also provided.

Claims (7)

1. A method for treatment of a neurological disorder and/or improvement of memory function in an individual in need thereof, the method comprising administering to the subject a compound of general structural formula (Ia)

wherein R1 to R9 are individually selected from H and CH3; and

R10 to R17 are individually selected from H, C═O, and OH;

or a salt thereof, in an amount effective to promote lactate secretion in the individual,

the neurological disorder is selected from the group consisting of arachnid cysts, attention deficit/hyperactivity disorder (ADHD), autism, bipolar disorder, catalepsy, depression, encephalitis, epilepsy/seizures, infection, locked-in syndrome, meningitis, migraine, multiple sclerosis, myelopathy, Alzheimer's disease, Huntington's disease, Parkinson's disease, Tourette's syndrome, and combinations thereof.

2. The method of claim 1 , wherein the compound is a macrolide.

3. The method of claim 1 , wherein the compound is lactonised between the carboxylic acid group at position 19 and the alcoholic group at position 3, creating an 18 atom ring to form compound A:

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2022
From: SOCIÉTÉ DES PRODUITS NESTLÉ SA
To: GLIAPHARM SA
Reel/Frame 062208/0283 →
MERGER Recorded Apr 14, 2022
From: NESTEC S.A.
To: SOCIETE DES PRODUITS NESTLE S.A.
Reel/Frame 059598/0399 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2022
From: BARRON, DENIS MARCEL; CICLET, OLIVIER; GRAND-GUILLAUME-PERRENOUD, ALEXANDRE; NARANJO PINTA, MARTINE; RATINAUD, YANN; THEVENET, JONATHAN; WIEDERKEHR, ANDREAS
To: NESTEC S.A.
Reel/Frame 059691/0095 →